Table 2 Summarized treatment course of the patient
From: Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report
Time of admission | 2018.11 | 2019.3 | 2021.6 |
|---|---|---|---|
RVSPa (mmHg) | 60 | 69 | 78 |
PAa(mm) | 27 | 30 | 30 |
EFa (%) | 62 | 53 | 52 |
TAPSE a(mm) | 17 | 12 | 10 |
RV a (mm) | 48 | 53 | 60 |
NT-proBNP(ng/ml, pre-treatment) | 2482 | 2572 | 3445 |
NT-proBNP(ng/ml, post-treatment) | 780 | 650 | 846 |
Functional class (NYHA, pre-treatment) | III | III | III |
Functional class (NYHA, post-treatment) | II | II | II |
PAH-target drugs | Tadalafil (10 mg,qd) | Tadalafil (20 mg,qd) Macitentan(10 mg,qd) | Tadalafil (20 mg,qd) Macitentan(10 mg,qd) |